Putative differentiating agents.
| Agent . | In Vitro Activity . | Clinical Activity . |
|---|---|---|
| Retinoids (ATRA) | Broad | APL |
| Interferons | Leukemia | — |
| Vitamin D3 | Broad | — |
| Butyrates | Broad | — |
| Polar-planar compound (HMBA, DMSO) | Broad | — |
| Protein Kinase C Activators (Phorbol esters, Bryostatin-1) | Leukemia | — |
| Amifostine | — | ? MDS |
| Cytotoxic Drugs (Ara-C, Hydroxyurea, 5-Azacytidine) | Leukemia | ? MDS |
| Growth factors/Cytokines | Leukemia | MDS, CML |
| Abbreviations: HMBA, hexamethylene bisacetamide; DMSO, dimethylsulfoxide; ATRA, all-trans retinoic acid; APL, acute promyelocytic leukemia; MDS, myelodysplastic syndrome | ||
| Agent . | In Vitro Activity . | Clinical Activity . |
|---|---|---|
| Retinoids (ATRA) | Broad | APL |
| Interferons | Leukemia | — |
| Vitamin D3 | Broad | — |
| Butyrates | Broad | — |
| Polar-planar compound (HMBA, DMSO) | Broad | — |
| Protein Kinase C Activators (Phorbol esters, Bryostatin-1) | Leukemia | — |
| Amifostine | — | ? MDS |
| Cytotoxic Drugs (Ara-C, Hydroxyurea, 5-Azacytidine) | Leukemia | ? MDS |
| Growth factors/Cytokines | Leukemia | MDS, CML |
| Abbreviations: HMBA, hexamethylene bisacetamide; DMSO, dimethylsulfoxide; ATRA, all-trans retinoic acid; APL, acute promyelocytic leukemia; MDS, myelodysplastic syndrome | ||